Calluna Pharma is developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source.
Calluna Pharma has raised $81.4M in total funding. The most recent round was Series A. The last funding was announced in January 2024.
Calluna Pharma's investors include Forbion Capital Partners, Investinor, Sarsia, p53.
Calluna Pharma is headquartered in Oslo, Norway.
Calluna Pharma is developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source.
Calluna Pharma is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Calluna Pharma — Funding & Investors." VCBacked, January 23, 2024, https://www.vcbacked.co/company/calluna-pharma. Accessed November 13, 2026.
VCBacked. (2024). Calluna Pharma — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/calluna-pharma
{{cite web |title=Calluna Pharma — Funding & Investors |url=https://www.vcbacked.co/company/calluna-pharma |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Calluna Pharma? Request a listing update